President, CSO, Founder AccuTheranostics, Inc PROI Foundation
State University at Buffalo, USA
Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human microvascular umbilical cord endothelium for lining stents. Besides her research, for the Chief of Staff, her responsibilities also included training ‘incoming” academic interns. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the 1st Place - Award for Excellence in Research from the American Federation for Clinical Research, and the 1st Place - Award for Excellence in Research – SUNY at Buffalo, Roswell Park Cancer Institute Research Forum. In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemosensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea od Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer personized treatment regimens. Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA. She has been and will be an invited speaker at various domestic and international scientific meetings including: Invited Speaker: Proceedings of the 6th Int l Conf on Frontiers of Polymers and Adv Materials, Recife, Brazil, March 2001; Key Note Speaker: Cancer Science 3rd World Congress Oct. 21, 2013 – San Francisco, CA; Plenary Speaker, Cancer Science 4th World Congress: Valencia, Spain, Sept. 1-3, 2015; International Expert and Key Note Speaker: INDO-GLOBAL HEALTHCARE SUMMIT & EXPO 2014, Hyderabad, India from July 23-26, 2015; Key Note Speaker: Dubai, United Arab Emirates, Aug 27-29, 2015; Keynote Speaker Gynecologic Oncology, May 19-21, 2016, San Antonio, Tx. Dr. Bradford also holds one patent: U.S. Patent No. 6485714 and has just applied for 3 more (2016) – patents pending.
Cancer Prevention and Treatment Personalized Medicine and Taking Methodologies from Bench-to-Bedside.